Switching CGRP(r) MoAbs in migraine: what evidence?
- 3 May 2024
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 24 (5) , 327-333
Abstract
Approximately 50% of patients that receive a CGRP(r) MoAb for the preventative treatment of migraine are expected to discontinue therapy. For patients that discontinue CGRP(r) MoAb therapy, few clinical options are available. One potential option is to switch CGRP(r) MoAbs, however, data concerning the efficacy of this intervention is scarce. This manuscript aims to summarize all available data concerning the potential efficacy of switching CGRP(r) MoAbs following previous medication discontinuation. Data was sourced by completing a database search for the terms: 'CGRP monoclonal antibody switch OR CGRP monoclonal antibody switching.' While data considering the potential efficacy of CGRP(r) switching continues to grow, our expert opinion supports the most recent European Headache Federation statement regarding CGRP(r) MoAb prescribing practices, concluding that there remains insufficient data to determine the efficacy of this intervention. As this topic is of significant clinical importance, we recommend a call-to-action to expand on current data considering the therapeutic options for patients that discontinue CGRP(r) MoAb therapy.Keywords
This publication has 47 references indexed in Scilit:
- Real-world effectiveness of erenumab in Japanese patients with migraineHeliyon, 2024
- Switching between anti-calcitonin gene-related peptide monoclonal antibodies: A comparison of monthly and quarterly dosingJournal of the Neurological Sciences, 2023
- Update of Gepants in the Treatment of Chronic MigraineCurrent Pain and Headache Reports, 2023
- Long-Term Effect of Switching From an Anti-CGRP Receptor to an Anti-CGRP Ligand Antibody in Treatment-Refractory Chronic Migraine: A Prospective Real-World AnalysisNeurotherapeutics, 2023
- Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting SystemAdvances in Therapy, 2022
- Chronic MigraineNeurologic Clinics, 2022
- Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative ReviewAdvances in Therapy, 2020
- Population Pharmacokinetics of Galcanezumab, an Anti‐CGRP Antibody, Following Subcutaneous Dosing to Healthy Individuals and Patients With MigraineThe Journal of Clinical Pharmacology, 2019
- Fremanezumab: First Global ApprovalDrugs, 2018
- Phase I, Randomized, Double‐blind, Placebo‐controlled, Single‐dose, and Multiple‐dose Studies of Erenumab in Healthy Subjects and Patients With MigraineClinical Pharmacology & Therapeutics, 2017